Confronta i metodi

	Saggio di emolisi	CAM Assay	Saggio Live/Dead
Campo	Biomateriali	Biomateriali	Biomateriali
Famiglia	Process / pipeline	Process / pipeline	Process / pipeline
Anno di origine	1950	1974	2000
Ideatore	Clinical hematology traditions	Judah Folkman	Invitrogen/Molecular Probes
Tipo	Hemolytic compatibility assay	Developmental biology assay	Dual-dye viability assay
Fonte seminale	ASTM F756-17 (2017). Standard Practice for Assessment of Hemolytic Properties of Materials. ASTM International.	Folkman, J. (1974). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine, 285(21), 1182-1186.	Molecular Probes (2004). LIVE/DEAD Viability/Cytotoxicity Kit user guide. Invitrogen Corporation.
Alias	RBC lysis assay, hemolytic compatibility test, hemolytic potential test	chick embryo chorioallantoic membrane, angiogenesis assay, CAM angiogenesis model	calcein-AM/propidium iodide, SYTO/PI staining, fluorescent viability stain
Correlati	4	4	4
Sintesi	The hemolysis assay is a standard method for evaluating the blood compatibility of biomaterials by quantifying the extent to which a material or substance damages red blood cells (RBCs) and causes hemoglobin release. Codified in standards including ASTM F756 and ISO 10993-4, the hemolysis assay is essential for regulatory approval of blood-contacting devices such as stents, catheters, artificial heart valves, and hemodialysis membranes. The assay provides a simple, quantitative measure of hemolytic potential that correlates with clinical safety.	The chorioallantoic membrane (CAM) assay is a well-established in vivo model for studying angiogenesis (new blood vessel formation) and evaluating the pro- or anti-angiogenic properties of biomaterials, drugs, and bioactive molecules. Developed by Judah Folkman in the 1970s, the assay uses the highly vascularized CAM of developing chick embryos as a platform for implanting test materials and observing vascular response. The CAM provides a transparent, immunologically naive microenvironment with rapid and reproducible neovascularization, making it ideal for screening angiogenic potential and assessing biomaterial biocompatibility.	The Live/Dead assay is a fluorescence-based method for simultaneously identifying live and dead cells using two complementary dyes. The assay combines calcein-AM (or SYTO fluorophores), which generates bright green fluorescence in living cells with intact esterase activity, with propidium iodide (PI), which produces red fluorescence in dead cells with compromised membrane integrity. Commercially developed by Molecular Probes and now part of Thermo Fisher's portfolio, the Live/Dead kit is widely used to evaluate cell viability on biomaterial scaffolds, in tissue constructs, and following drug or toxin exposure.